Article
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Oncology reports - 1 Sept 2013
Krawczyk Paweł, Kowalski Dariusz M, Krawczyk Kamila Wojas, Szczyrek Michał, Mlak Radosław, Rolski Andrzej, Szudy Aneta, Kieszko Robert, Winiarczyk Kinga, Milanowski Janusz, Krzakowski Maciej
Abstract excerpt
Erlotinib is a reversible tyrosine kinase inhibitor of epidermal growth factor receptor (TKI EGFR). In Poland, as of July 2012, it is used in the treatment only of patients with non-small cell lung cancer (NSCLC) and with EGFR mutation gene after standard chemotherapy failure. The effectiveness of erlotinib in second- or third-line treatment of NSCLC patients without EGFR activating mutation gene remains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.